Suven Pharmaceuticals and Cohance Lifesciences Join Forces in Transformative Merger
Suven Pharmaceuticals and Cohance Lifesciences, a CDMO platform, have announced a proposed merger. Shareholders of Cohance will receive 11 shares of Suven for every 295 shares held. The transaction is expected to be completed in 12-15 months, subject to regulatory approvals....